Supplementary file 2

Results of Shapiro normality tests for ANOVA testing the effects of group and phase on behavioral metrics

A/ Normality tests on Activity time ratio in each group x phase condition

- Before removing 3 extreme outliers

| Group            | Phase | Statistic (W) | p-value |
|------------------|-------|---------------|---------|
| bvFTD patients   | Free  | .94           | .22     |
| healthy controls | Free  | .77           | .001    |
| bvFTD patients   | Guided| .83           | .003    |
| healthy controls | Guided| .51           | < .001  |

- After removing 3 extreme outliers

| Group            | Phase | Statistic (W) | p-value |
|------------------|-------|---------------|---------|
| bvFTD patients   | Free  | .94           | .22     |
| healthy controls | Free  | .79           | .003    |
| bvFTD patients   | Guided| .83           | .003    |
| healthy controls | Guided| .90           | .10     |

B/ Normality tests on Walking occurrences in each group x phase condition

(No detected extreme outliers)

| Group            | Phase | Statistic (W) | p-value |
|------------------|-------|---------------|---------|
| bvFTD patients   | Free  | .90           | .05     |
| healthy controls | Free  | .86           | .02     |
| bvFTD patients   | Guided| .86           | .007    |
| healthy controls | Guided| .97           | .836    |
C/ Normality tests on *Walking acceleration* in each group x phase condition

- Before removing 2 extreme outliers

| Group             | Phase | Statistic (W) | p-value |
|-------------------|-------|---------------|---------|
| bvFTD patients    | Free  | .93           | .16     |
| healthy controls  | Free  | .92           | .22     |
| bvFTD patients    | Guided| .96           | .51     |
| healthy controls  | Guided| .75           | .001    |

- After removing 2 extreme outliers

| Group             | Phase | Statistic (W) | p-value |
|-------------------|-------|---------------|---------|
| bvFTD patients    | Free  | .96           | .62     |
| healthy controls  | Free  | .92           | .23     |
| bvFTD patients    | Guided| .96           | .51     |
| healthy controls  | Guided| .92           | .26     |

D/ Normality tests on *Walking duration* in each group x phase condition

- Before removing 1 extreme outlier

| Group             | Phase | Statistic (W) | p-value |
|-------------------|-------|---------------|---------|
| bvFTD patients    | Free  | .93           | .18     |
| healthy controls  | Free  | .84           | .01     |
| bvFTD patients    | Guided| .93           | .16     |
| healthy controls  | Guided| .96           | .64     |
- After removing 1 extreme outlier

| Group            | Phase | Statistic (W) | p-value |
|------------------|-------|---------------|---------|
| bvFTD patients   | Free  | .93           | .18     |
| healthy controls | Free  | .93           | .30     |
| bvFTD patients   | Guided| .93           | .16     |
| healthy controls | Guided| .96           | .64     |